Table 3.
Observed and expected numbers of cancers and SIRs among non-transplanted and PLT patients with CF in France from 2006 to 2017.
| Non-transplanted patients | Transplanted patients after PLT | |||||
|---|---|---|---|---|---|---|
| Site (ICD-10 code) | Observed N incident cancers | Expected N cancers in general population | SIR (95% CI) | Observed N incident cancers | Expected N cancers in general population | SIR (95%CI) |
| All cancers | 86 | 33.52 | 2.57 (2.05 to 3.17) | 125 | 6.32 | 19.76 (16.45 to 23.55) |
| Oesophagus | 2 | 0.27 | 7.47 (0.90 to 26.97) | 0 | 0.05 | 0.00 (0.00 to 64.22) |
| Stomach | 0 | 0.37 | 0.00 (0.00 to 8.04) | 3 | 0.08 | 37.76 (7.79 to 110.35) |
| Small intestine | 1 | 0.06 | 16.95 (0.43 to 94.41) | 4 | 0.01 | 317.53 (86.52 to 812.99) |
| Colorectal | 6 | 1.36 | 4.41 (1.62 to 9.59) | 6 | 0.23 | 26.45 (9.71 to 57.58) |
| Pancreas | 1 | 0.55 | 1.80 (0.05 to 10.05) | 3 | 0.10 | 30.79 (6.35 to 90.00) |
| Lip, oral cavity and pharynx | 4 | 1.21 | 3.30 (0.90 to 8.44) | 4 | 0.24 | 16.97 (4.62 to 43.46) |
| Nasal cavities, paranasal sinuses, middle and inner ear | 0 | 0.06 | 0.00 (0.00 to 47.17) | 1 | 0.01 | 81.07 (2.05 to 451.71) |
| Larynx | 0 | 0.20 | 0.00 (0.00 to 14.84) | 1 | 0.04 | 26.06 (0.66 to 145.22) |
| Lung | 12 | 2.42 | 4.96 (2.57 to 8.67) | 19 | 0.47 | 40.36 (24.30 to 63.03) |
| Bone sarcoma | 2 | 0.30 | 6.62 (0.80 to 23.92) | 1 | 0.02 | 42.63 (1.08 to 237.54) |
| Malignant melanoma and skin cancers* | 9 | 2.13 | 39 | 0.54 | ||
| Soft tissue sarcoma | 1 | 0.57 | 1.76 (0.04 to 9.81) | 1 | 0.08 | 11.77 (0.30 to 65.58) |
| Breast | 8 | 5.51 | 1.45 (0.63 to 2.86) | 1 | 1.6 | 0.62 (0.02 to 3.48) |
| Cervix uteri | 2 | 0.55 | 3.61 (0.44 to 13.03) | 3 | 0.19 | 16.19 (3.34 to 47.31) |
| Corpus uteri | 1 | 0.42 | 2.37 (0.06 to 13.19) | 0 | 0.06 | 0.00 (0.00 to 53.19) |
| Ovary | 1 | 0.50 | 2.01 (0.05 to 11.18) | 0 | 0.09 | 0.00 (0.00 to 33.11) |
| Prostate | 2 | 1.37 | 1.46 (0.18 to 5.27) | 1 | 0.12 | 8.29 (0.21 to 46.16) |
| Testis | 1 | 1.79 | 0.56 (0.01 to 3.12) | 3 | 0.39 | 7.62 (1.57 to 22.28) |
| Kidney | 2 | 1.15 | 1.74 (0.21 to 6.30) | 4 | 0.22 | 18.29 (4.98 to 46.84) |
| Bladder | 1 | 0.41 | 2.46 (0.06 to 13.73) | 3 | 0.06 | 51.40 (10.60 to 150.20) |
| Central nervous system (CNS) | 0 | 1.40 | 0.00 (0.00 to 2.14) | 2 | 0.19 | 10.77 (1.30 to 38.92) |
| Thyroid gland | 2 | 2.63 | 0.76 (0.09 to 2.75) | 1 | 0.69 | 1.44 (0.04 to 8.03) |
| Hodgkin's lymphoma | 3 | 1.50 | 1.99 (0.41 to 5.83) | 3 | 0.22 | 13.58 (2.80 to 39.69) |
| Non-Hodgkin lymphoma | 2 | 3.12 | 0.64 (0.08 to 2.31) | 5 | 0.37 | 13.68 (4.44 to 31.92) |
| Acute myeloid leukemia | 2 | 0.57 | 3.54 (0.43 to 12.77) | 1 | 0.07 | 14.72 (0.37 to 82.06) |
| Chronic myeloid leukemia (LMC) | 1 | 0.12 | 8.65 (0.22 to 48.22) | 0 | 0.02 | 0.00 (0.00 to 125.31) |
No cancer were observed for vulva, vagina, penis, uveal melanoma, chronic myelomonocytic leukaemia, liver and, intrahepatic bileduct, gallblader and extrahepatic bileduct.
*Expected number of cancers includes only melanoma. We thus could not calculate SIR for this entity.